Literature DB >> 25376282

Epidemiological trends of hepatocellular carcinoma in Austria.

Matthias Pinter1, Florian Hucke, Nadine Zielonke, Michael Trauner, Wolfgang Sieghart, Markus Peck-Radosavljevic.   

Abstract

BACKGROUND/AIMS: The heterogeneous epidemiology of hepatocellular carcinoma (HCC) with the highest incidence rates in East Asia, sub-Saharan Africa and Melanesia results from variations in the main risk factors. We investigated epidemiological trends, including incidence and mortality, of patients diagnosed with HCC over a 20-year period in Austria.
METHODS: Data on age-adjusted incidence rates of HCC were obtained from the Austrian National Cancer Registry, which compiles nationwide data on all newly diagnosed cancers. Data on age-adjusted mortality were obtained from the national death registry (Statistics Austria).
RESULTS: Of 24,939 patients diagnosed with hepatobiliary tumors between 1990 and 2009, 8,561 subjects had HCC (m/f ratio 75/25%; mean age 69 years). Lymph node and distant metastases were present in 7.5 and 12.2%, respectively. The age-adjusted incidence rate was significantly higher in men than women (m/f ratio 4.5/1) and markedly increased in men (4.68/5.10) but remained stable in women (1.18/1.11). Similarly, the age-adjusted mortality rate was significantly higher in men than women (m/f ratio 4.5/1), increased in men (4.02/4.98) and remained stable in women (0.92/1.0). The median overall survival was 4.5 months for men and 3.2 months for women with 1-/5-year survival rates of 33/11% and 28/10%, respectively.
CONCLUSION: HCC is the most common hepatobiliary neoplasia in Austria and has a very poor prognosis. The age-adjusted incidence and mortality rates were higher in males, increased over time in men and remained stable in women. Extrahepatic metastases were rarely diagnosed and associated with dismal survival.

Entities:  

Mesh:

Year:  2014        PMID: 25376282     DOI: 10.1159/000367983

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  5 in total

Review 1.  Disease Burden of Hepatocellular Carcinoma: A Global Perspective.

Authors:  Mehmet Sayiner; Pegah Golabi; Zobair M Younossi
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

2.  Changing Epidemiological Trends of Hepatobiliary Carcinomas in Austria 2010-2018.

Authors:  Florian Hucke; Matthias Pinter; Miriam Hucke; Simona Bota; Dajana Bolf; Monika Hackl; Markus Peck-Radosavljevic
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

3.  Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort.

Authors:  Bernhard Scheiner; Martha M Kirstein; Florian Hucke; Fabian Finkelmeier; Kornelius Schulze; Johann von Felden; Sandra Koch; Philipp Schwabl; Jan B Hinrichs; Fredrik Waneck; Oliver Waidmann; Thomas Reiberger; Christian Müller; Wolfgang Sieghart; Michael Trauner; Arndt Weinmann; Henning Wege; Jörg Trojan; Markus Peck-Radosavljevic; Arndt Vogel; Matthias Pinter
Journal:  Aliment Pharmacol Ther       Date:  2019-04-12       Impact factor: 8.171

Review 4.  Review article: systemic treatment of hepatocellular carcinoma.

Authors:  Matthias Pinter; Markus Peck-Radosavljevic
Journal:  Aliment Pharmacol Ther       Date:  2018-07-23       Impact factor: 8.171

Review 5.  Long-term remission in advanced stage hepatocellular carcinoma? A chance for cure?

Authors:  Matthias Pinter; Wolfgang Sieghart
Journal:  Memo       Date:  2018-08-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.